Financial Performance - The company's operating revenue for Q3 2025 was ¥79,116,439.38, representing a 42.81% increase compared to the same period last year[5] - The net profit attributable to shareholders was -¥1,803,988.01, a decrease of 138.94% year-on-year[5] - The net cash flow from operating activities was -¥82,112,667.84, reflecting a significant decline of 446.24% compared to the previous year[5] - The total revenue for the first nine months of 2025 was ¥344,363,431.23, a decrease of 30.06% compared to the same period in 2024[11] - Total operating revenue for the current period was CNY 344,363,431.23, a decrease of 30.1% compared to CNY 492,343,391.10 in the previous period[24] - Net profit for the current period was a loss of CNY 11,836,617.81, compared to a profit of CNY 20,046,304.69 in the previous period[25] - The company reported a basic and diluted earnings per share of -0.1054, compared to 0.2 in the previous period[25] Assets and Liabilities - Total assets at the end of Q3 2025 amounted to ¥2,061,421,440.55, an increase of 5.88% from the end of the previous year[5] - Total assets increased to CNY 2,061,421,440.55 from CNY 1,946,989,678.97, reflecting a growth of 5.9%[22] - Total liabilities rose to CNY 843,970,537.72, up from CNY 661,987,013.29, marking an increase of 27.5%[22] - Non-current liabilities increased to CNY 82,052,994.82 from CNY 45,889,360.39, representing an increase of 78.5%[22] - The company's total equity decreased to CNY 1,217,450,902.83 from CNY 1,285,002,665.68, a decline of 5.3%[22] Cash Flow - The company's cash and cash equivalents at the end of the period were ¥199,145,167.48, a decrease of 39.70% from the previous year[13] - The net cash flow from operating activities was -$82.11 million, compared to -$15.03 million in the previous period, indicating a decline in operational performance[27] - Cash outflows from operating activities totaled $537.11 million, down from $623.68 million year-over-year[27] - The net cash flow from investing activities was -$338.27 million, compared to -$253.54 million in the previous period, reflecting increased investment expenditures[27] - Cash inflows from investing activities decreased significantly to $330.36 million from $619.20 million year-over-year[27] - The net cash flow from financing activities was $43.66 million, a recovery from a negative $41.42 million in the previous period[27] - Total cash and cash equivalents at the end of the period were $199.15 million, down from $330.26 million at the end of the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 7,506[14] - The largest shareholder, Chen Yong, holds 27.77% of shares, totaling 27,774,000 shares[14] - GT South (Hong Kong) Limited is the second-largest shareholder with an 11.50% stake, amounting to 11,500,000 shares[14] - The total number of restricted shares at the end of the period is 4,818,000, with 4,334,000 shares released during the period[17] - The company has no preferred shareholders or preferred shares outstanding[15] Borrowings and Inventory - The company experienced a 51.08% increase in short-term loans, totaling ¥219,988,853.95, due to increased funding needs for operations[10] - The company reported a significant increase in long-term borrowings by 478.57%, reaching ¥48,600,000.00, primarily due to share repurchase loans[10] - The inventory increased by 56.20% to ¥318,974,199.70, attributed to increased investments in ongoing projects[10] - Inventory increased significantly to ¥318,974,199.70 from ¥204,203,626.98, indicating a 56% rise[20] Stock Incentive Plan - The company plans to implement a stock incentive plan as approved in the recent board and shareholder meetings[18]

Group 1 - The core business of Sichuan Portong Medical Equipment Group Co., Ltd. includes providing medical gas systems and clean operating room solutions, with revenue composition being 55.69% from clean equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical device sales, 2.81% from operation and maintenance services, and 0.14% from other sources [2] - As of October 20, 2023, the number of shareholders for Portong Medical is 7,545, a decrease of 0.22% from the previous period, while the average circulating shares per person increased by 0.23% to 8,355 shares [2] - For the first half of 2025, Portong Medical reported a revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to the parent company of -8.4044 million yuan, a year-on-year decrease of 154.53% [2] Group 2 - On October 24, 2023, Portong Medical's stock price increased by 0.09%, with a trading volume of 23.3597 million yuan [1] - The financing data for Portong Medical on the same day showed a financing purchase amount of 1.1985 million yuan and a financing repayment of 1.2386 million yuan, resulting in a net financing outflow of 40,000 yuan [1] - The total balance of margin trading for Portong Medical as of October 24, 2023, is 37.386 million yuan, which accounts for 2.45% of its circulating market value, indicating a low financing balance compared to the past year [1] Group 3 - Portong Medical has distributed a total of 48.9973 million yuan in dividends since its A-share listing [3]

Core Viewpoint - As of October 24, 2025, the stock price of Kangtong Medical (301515) closed at 21.92 yuan, reflecting a slight increase of 0.09% with a trading volume of 1.06 million shares and a total transaction value of 23.36 million yuan [1] Financial Performance - Kangtong Medical reported a main revenue of 265 million yuan for the first half of 2025, a year-on-year decline of 39.29% [3] - The net profit attributable to shareholders was -8.4044 million yuan, a year-on-year decrease of 154.53% [3] - The second quarter of 2025 saw a single-quarter main revenue of 241 million yuan, down 33.22% year-on-year, and a net profit of -9.9834 million yuan, a decline of 312.13% [3] - The company’s gross profit margin stood at 22.09%, significantly lower than the industry average of 51.33% [3] Market Position - The total market capitalization of Kangtong Medical is 2.192 billion yuan, which is below the industry average of 11.653 billion yuan, ranking 118 out of 124 in the medical device industry [3] - The company’s price-to-earnings ratio (P/E) is -130.41, compared to the industry average of 95.02, indicating a challenging profitability outlook [3] - The return on equity (ROE) is -0.67%, while the industry average is 2.09%, reflecting underperformance in generating returns for shareholders [3] Capital Flow Analysis - On October 24, 2025, the net inflow of main funds was 1.4429 million yuan, accounting for 6.18% of the total transaction value [2] - Retail investors experienced a net outflow of 1.0009 million yuan, representing 4.28% of the total transaction value [2] - Over the past five days, the stock has seen fluctuating capital flows, with significant net outflows from main and retail investors on several days [2]

中国经济网北京10月22日讯港通医疗（301515）(301515.SZ)日前披露2025年半年度报告。2025年上半年，公司实 现营业收入2.65亿元，同比下降39.29%；归属于上市公司股东的净利润为-840.44万元，上年同期为1541.37万元； 归属于上市公司股东的扣除非经常性损益的净利润为-1026.93万元，上年同期为1359.35万元；经营活动产生的现金 流量净额为-3914.90万元。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入(元) | 265,246,991.85 | 436, 943, 414. 18 | -39. 29% | | 归属于上市公司股东的净利 润(元) | -8, 404, 410. 35 | 15, 413, 688. 07 | -154. 53% | | 归属于上市公司股东的扣除 非经常性损益的净利润 | -10,269,336.53 | 13, 593, 482. 70 | -175. 55% | | (元) | | | | | 经营活动产生的现金流量净 | -39.149.019 ...

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Kangtong Medical, indicating a slight increase in stock price and low financing balance [1][2] - On October 21, Kangtong Medical's stock rose by 1.58% with a trading volume of 23.12 million yuan, and the net financing purchase was 55,300 yuan [1] - As of October 21, the total financing and securities balance for Kangtong Medical was 37.34 million yuan, with the financing balance accounting for 2.45% of the circulating market value, which is below the 50th percentile level over the past year [1][2] Group 2 - Kangtong Medical, established on January 13, 1998, specializes in providing medical gas systems and clean operating room solutions, with main revenue sources being clean equipment and systems (55.69%) and medical gas equipment and systems (37.30%) [2] - For the first half of 2025, Kangtong Medical reported a revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to shareholders of -8.40 million yuan, a decline of 154.53% [2] - The company has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]

证券日报网讯港通医疗10月21日在互动平台回答投资者提问时表示，公司截至2025年10月20日股东总户 数为7545户。 （文章来源：证券日报） ...

Group 1 - The core business of the company includes providing medical gas systems and clean operating room solutions, with revenue composition being 55.69% from clean equipment and systems, 37.30% from medical gas equipment and systems, 4.06% from medical device sales, 2.81% from operation and maintenance services, and 0.14% from other sources [2] - As of October 10, the number of shareholders for the company increased by 0.75% to 7,562, while the average circulating shares per person decreased by 0.74% to 8,336 shares [2] - For the first half of 2025, the company reported a revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to the parent company of -8.4044 million yuan, a year-on-year decrease of 154.53% [2] Group 2 - The company has distributed a total of 48.9973 million yuan in dividends since its A-share listing [3] Group 3 - On October 16, the company's stock price fell by 0.66%, with a trading volume of 11.0857 million yuan [1] - The financing buy-in amount on the same day was 493,400 yuan, while the financing repayment was 805,500 yuan, resulting in a net financing buy of -312,100 yuan [1] - The total financing and securities lending balance as of October 16 was 38.7272 million yuan, with the financing balance accounting for 2.62% of the circulating market value, indicating a relatively high level compared to the past year [1]

Group 1 - The core business of Sichuan Portong Medical Equipment Group Co., Ltd. includes providing overall solutions for medical institutions, focusing on medical gas systems and clean operating rooms [2] - As of October 10, the number of shareholders for Portong Medical increased by 0.75% to 7,562, while the average circulating shares per person decreased by 0.74% to 8,336 shares [2] - For the first half of 2025, Portong Medical reported a revenue of 265 million yuan, a year-on-year decrease of 39.29%, and a net profit attributable to the parent company of -8.4044 million yuan, a year-on-year decrease of 154.53% [2] Group 2 - On October 15, Portong Medical's stock price fell by 0.14%, with a trading volume of 18.3229 million yuan [1] - The financing data on October 15 showed a financing buy-in of 2.0963 million yuan and a financing repayment of 3.4550 million yuan, resulting in a net financing buy of -1.3587 million yuan [1] - The total balance of margin trading for Portong Medical as of October 15 was 39.0393 million yuan, with the financing balance accounting for 2.63% of the circulating market value, indicating a high level compared to the past year [1]

证券日报网讯港通医疗（301515）10月14日在互动平台回答投资者提问时表示，公司截至2025年10月10 日股东总户数为7562户。 ...

关于持股5%以上股东股权结构发生变动的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）于2025年9月25 日披露了《关于持股5%以上股东股权结构拟发生变动的公告》（公告编号： 2025-056），公司收到持股5%以上股东GT South(HongKong) Limited（以下简称 "香港GT"）的通知，其上层股东GT North(Cayman)Ltd.,（以下简称"开曼GT"） 的上层股东Ares Corporate Opportunities Fund Asia,L.P.（以下简称"Ares"） 与Ever Thrive Global Limited（以下简称"Ever Thrive"）共同签署了《股 权收购协议》，Ever Thrive拟受让Ares持有的开曼GT100%股权。股权转让完成 后，Ever Thrive变更为开曼GT唯一股东，Ever Thrive通过开曼GT和香港GT间接 持有公司11.50%股权（Ever Thrive持有开曼GT100%股权；开曼GT持有香港GT100% ...